Figure 3
Figure 3. Event-free survival of younger high-risk patients (18-60 years, aaIPI 2,3) treated on the MegaCHOEP phase III trial comparing conventional (8 × CHOEP-14) with repetitive high-dose therapy

Event-free survival of younger high-risk patients (18-60 years, aaIPI 2,3) treated on the MegaCHOEP phase III trial comparing conventional (8 × CHOEP-14) with repetitive high-dose therapy

Close Modal

or Create an Account

Close Modal
Close Modal